Literature DB >> 3497953

Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow.

T M Wick, J L Moake, M M Udden, S G Eskin, D A Sears, L V McIntire.   

Abstract

The interactions of normal erythrocytes and erythrocytes from patients having hemoglobin S hemoglobinopathies with normal human endothelial cells (EC) were investigated under flow conditions. When EC supernatant, containing 2.8-11.0 U/dl of von Willebrand factor (vWF) antigen and vWF multimeric forms larger than those present in normal plasma, was the red blood cell (RBC)-suspending medium instead of serum-free medium (SFM), the adhesion of sickle RBC, but not normal RBC, to endothelial cells was greatly increased (range of enhancement of sickle RBC adhesion, 2- to 27-fold). Adhesion of sickle RBC to endothelial cells was reduced to near serum-free levels when EC supernatant was immunologically depleted of vWF forms. Sickle RBC suspended in SFM containing 200 U/dl of purified vWF multimers of the type found in normal human plasma or 300 micrograms/ml human fibronectin were only slightly more adhesive to endothelial cells than sickle RBC suspended in SFM alone. These data indicate that unusually large vWF multimers produced by endothelial cells are potent mediators of the adhesion of sickle erythrocytes to endothelial cells. Vaso-occlusive crises in sickle cell anemia may be caused, at least in part, by adhesive interactions between the abnormal surfaces of sickle RBC and the endothelium after the release of unusually large vWF multimeric forms from stimulated or damaged endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497953      PMCID: PMC442320          DOI: 10.1172/JCI113151

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Solid-phase immunoradiometric assay of factor-VIII protein.

Authors:  R B Counts
Journal:  Br J Haematol       Date:  1975-12       Impact factor: 6.998

2.  Altered Factor VIII complexes in sickle cell disease.

Authors:  I Mackie; H Bull; M Brozović
Journal:  Br J Haematol       Date:  1980-11       Impact factor: 6.998

3.  Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease.

Authors:  R P Hebbel; O Yamada; C F Moldow; H S Jacob; J G White; J W Eaton
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

4.  Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures.

Authors:  R Hoover; R Rubin; G Wise; R Warren
Journal:  Blood       Date:  1979-10       Impact factor: 22.113

5.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

6.  Synthesis of antihemophilic factor antigen by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

7.  Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.

Authors:  R P Hebbel; M A Boogaerts; J W Eaton; M H Steinberg
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

8.  Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.

Authors:  L W Hoyer; J R Shainoff
Journal:  Blood       Date:  1980-06       Impact factor: 22.113

9.  Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes.

Authors:  R Nachman; R Levine; E A Jaffe
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  Synthesis of fibronectin by cultured human endothelial cells.

Authors:  E A Jaffe; D F Mosher
Journal:  J Exp Med       Date:  1978-06-01       Impact factor: 14.307

View more
  32 in total

1.  Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Authors:  Diana R Gutsaeva; James B Parkerson; Shobha D Yerigenahally; Jeffrey C Kurz; Robert G Schaub; Tohru Ikuta; C Alvin Head
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

Review 2.  Sickle cell disease: old discoveries, new concepts, and future promise.

Authors:  Paul S Frenette; George F Atweh
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

Review 3.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

4.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

5.  Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications.

Authors:  D K Kaul; M E Fabry; R L Nagel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm.

Authors:  Aslihan Turhan; Linnea A Weiss; Narla Mohandas; Barry S Coller; Paul S Frenette
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

7.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

Review 8.  The multifaceted role of ischemia/reperfusion in sickle cell anemia.

Authors:  Robert P Hebbel; John D Belcher; Gregory M Vercellotti
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 9.  Sickle cell vasoocclusion: many issues and some answers.

Authors:  D K Kaul; R L Nagel
Journal:  Experientia       Date:  1993-01-15

Review 10.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.